The influenza antiviral favipiravir was tested in clinical trials with COVID-19 patients in China and showed a shorter viral clearance time than the control group that received the anti-HIV combo lopinavir/ritonavir.
Credit: Antipina Daria via Shutterstock. Treatment options for COVID-19 are urgently needed as the total number of confirmed cases globally rises to 550,000 on Friday and the US becomes the country with the most confirmed cases, at over 86,000.
One of the potentially quickest ways to find treatment is to test substances already approved or in development for other indications.
The influenza antiviral favipiravir, marketed as Avigan by Fujifilm Toyama in Japan, was tested in clinical trials with COVID-19 patients in China and